S'abonner

Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency - 07/03/18

Doi : 10.1016/j.jaci.2017.05.030 
Daniel Petersheim, MD a, , , Michel J. Massaad, PhD a, , Saetbyul Lee, PhD a, Alessia Scarselli, MD b, Caterina Cancrini, MD b, Kunihiko Moriya, MD, PhD c, Yoji Sasahara, MD, PhD c, Arjan C. Lankester, MD, PhD d, Morna Dorsey, MD e, Daniela Di Giovanni, MD f, Liliana Bezrodnik, MD f, Hidenori Ohnishi, MD, PhD g, Ryuta Nishikomori, MD h, Kay Tanita, MD i, Hirokazu Kanegane, MD, PhD i, Tomohiro Morio, MD i, Erwin W. Gelfand, MD j, Ashish Jain, MD k, Elizabeth Secord, MD, PhD l, Capucine Picard, MD, PhD m, Jean-Laurent Casanova, MD, PhD m, n, Michael H. Albert, MD o, Troy R. Torgerson, MD, PhD p, Raif S. Geha, MD a,
a Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass 
b Division of Immunology and Infectious Diseases, Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, and University of Rome Tor Vergata, Rome, Italy 
c Department of Pediatrics, Tohoku University, Tohoku, Japan 
d Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands 
e Division of Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, Calif 
f Immunology Service, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina 
g Department of Pediatrics, Gifu University, Gifu, Japan 
h Department of Pediatrics, Kyoto University, Kyoto, Japan 
i Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan 
j Immunodeficiency Diagnosis and Treatment Program, Department of Pediatrics, National Jewish Health, Denver, Colo 
k Merck Research Laboratories Boston, Boston, Mass 
l Division of Allergy, Asthma, and Immunology, Children's Hospital of Michigan, Detroit, Mich 
m Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital, Paris Descartes University, Paris, France 
n St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 
o Department of Pediatric Hematology and Oncology, Dr von Hauner University Children's Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany 
p Department of Pediatrics, University of Washington School of Medicine, Seattle, Wash 

Corresponding author: Raif S. Geha, MD, One Blackfan Circle, Boston, MA 02115.One Blackfan CircleBostonMA02115

Abstract

Background

Autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency (AD EDA-ID) is caused by heterozygous point mutations at or close to serine 32 and serine 36 or N-terminal truncations in IκBα that impair its phosphorylation and degradation and thus activation of the canonical nuclear factor κ light chain enhancer of activated B cells (NF-κB) pathway. The outcome of hematopoietic stem cell transplantation is poor in patients with AD EDA-ID despite achievement of chimerism. Mice heterozygous for the serine 32I mutation in IκBα have impaired noncanonical NF-κB activity and defective lymphorganogenesis.

Objective

We sought to establish genotype-phenotype correlation in patients with AD EDA-ID.

Methods

A disease severity scoring system was devised. Stability of IκBα mutants was examined in transfected cells. Immunologic, biochemical, and gene expression analyses were performed to evaluate canonical and noncanonical NF-κB signaling in skin-derived fibroblasts.

Results

Disease severity was greater in patients with IκBα point mutations than in those with truncation mutations. IκBα point mutants were expressed at significantly higher levels in transfectants compared with truncation mutants. Canonical NF-κB–dependent IL-6 secretion and upregulation of the NF-κB subunit 2/p100 and RELB proto-oncogene, NF-κB subunit (RelB) components of the noncanonical NF-κB pathway were diminished significantly more in patients with point mutations compared with those with truncations. Noncanonical NF-κB–driven generation of the transcriptionally active p100 cleavage product p52 and upregulation of CCL20, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1), which are important for lymphorganogenesis, were diminished significantly more in LPS plus α-lymphotoxin β receptor–stimulated fibroblasts from patients with point mutations compared with those with truncations.

Conclusions

IκBα point mutants accumulate at higher levels compared with truncation mutants and are associated with more severe disease and greater impairment of canonical and noncanonical NF-κB activity in patients with AD EDA-ID.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Ectodermal dysplasia with immune deficiency, NF-κB inhibitor α, canonical nuclear factor κB pathway, noncanonical nuclear factor κB pathway, lymphorganogenesis, hematopoietic stem cell transplantation

Abbreviations used : AD EDA-ID, DN, FKPM, GAPDH, HSCT, IκBα, ICAM-1, IKK, LN, LTo, LTβR, NF-κB, NF-κB1, NF-κB2, NIK, PID, qPCR, RelB, RNA-Seq, S32, S36, SLO, TLR, VCAM-1, WT


Plan


 Supported by a scholarship from the DAAD Thematic Network “Research for Rare Diseases and Personalized Medicine” and a Carl Duisberg scholarship from Bayer Foundations (to D.P.) and USPHS grant 1R21AI124101-01 (to R.S.G).
 Disclosure of potential conflict of interest: D. Petersheim receives grant support from the DAAD and Bayer Foundations. M. Dorsey receives travel support from CSL Behring and support from the National Institutes of Health (NIH). J.-L. Casanova serves on the board for ADMA; serves as a consultant for Pfizer, Novartis, Sanofi, Genetech, and Neovacs; and receives grant support from Merck Sharpe & Dohme and Biogen Idec. M. H. Albert provides expert testimony for Biotest; receives grant support from GlaxoSmithKline; received payment for lectures from MSD and Jazz; holds stock with Amgen, BMS, Biotest, and Juno; and received travel expenses from Octapharma, Medac, and Neovii. T. R. Torgerson serves as a consultant for Shire Biosciences, UCB Biopharma, CSL Behring, and ADMA Biosciences and receives grant support from Baxalta BioSciences and CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 3

P. 1060 - mars 2018 Retour au numéro
Article précédent Article précédent
  • Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation
  • Fayhan J. Alroqi, Louis-Marie Charbonnier, Safa Baris, Ayca Kiykim, Janet Chou, Craig D. Platt, Abdulrahman Algassim, Sevgi Keles, Bandar K. Al Saud, Fowzan S. Alkuraya, Michael Jordan, Raif S. Geha, Talal A. Chatila
| Article suivant Article suivant
  • Mechanistic link between diesel exhaust particles and respiratory reflexes
  • Ryan K. Robinson, Mark A. Birrell, John J. Adcock, Michael A. Wortley, Eric D. Dubuis, Shu Chen, Catriona M. McGilvery, Sheng Hu, Milo S.P. Shaffer, Sara J. Bonvini, Sarah A. Maher, Ian S. Mudway, Alexandra E. Porter, Chris Carlsten, Teresa D. Tetley, Maria G. Belvisi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.